44-Cent Pill: A New Hope for Some Autism Patients

A study by Yale University researchers suggests that levocarnitine, a widely available prescription medication, may offer a new treatment pathway for certain individuals with autism spectrum disorder. The drug, costing approximately 44 cents per pill, was screened among 774 FDA-approved medications for its impact on zebrafish genetically engineered to exhibit autism-like traits.

Levocarnitine, also known as Carnitor, showed a significant ability to improve the zebrafish's interpretation of and response to their environment. Scientists hypothesize that the medication could potentially enhance energy production in specific brain regions that exhibit low activity in some autistic individuals, such as those associated with language and emotional processing.

The research team emphasized that while these results are promising, they are preliminary. The zebrafish in the study carried specific autism-related genes, SCN2A and DYRK1A, found in a small percentage of the autism population. Extensive human clinical trials are required before levocarnitine can be considered a viable treatment for autism, a process that could take several years.

This investigation into levocarnitine's potential comes amid a notable increase in autism diagnoses in the United States, with experts citing factors like increased awareness and broader diagnostic criteria. Currently, no cure exists for autism, but ongoing research continues to explore new therapeutic avenues to alleviate severe symptoms.